Gyre Therapeutics reported a quarterly loss of $0.12 per share, worse than the Zacks Consensus Estimate loss of $0.08. This follows a prior-year profit of $0.02 per share, indicating a deterioration in results and an earnings miss versus expectations.
Gyre Therapeutics reported a quarterly loss of $0.12 per share, worse than the Zacks Consensus Estimate loss of $0.08. This follows a prior-year profit of $0.02 per share, indicating a deterioration in results and an earnings miss versus expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
